AlphaFold 3: an unprecedent opportunity for fundamental research and drug development
Precision Clinical Medicine · 28.06.2025 · 8 (3)
DOI: 10.1093/pcmedi/pbaf015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Precision Clinical Medicine, online erschienen am 01.07.2025. Verfasst von Ziqi Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST, Wenzhou Medical University, National Science Foundation of China.
Abstract (Originalsprache)
AlphaFold3 (AF3), as the latest generation of artificial intelligence model jointly developed by Google DeepMind and Isomorphic Labs, has been widely heralded in the scientific research community since its launch. With unprecedented accuracy, the AF3 model may successfully predict the structure and interactions of virtually all biomolecules, including proteins, ligands, nucleic acids, ions, etc. By accurately simulating the structural information and interactions of biomacromolecules, it has shown great potential in many aspects of structural prediction, mechanism research, drug design, protein engineering, vaccine development, and precision therapy. In order to further understand the characteristics of AF3 and accelerate its promotion, this article sets out to address the development process, working principle, and application in drugs and biomedicine, especially focusing on the intricate differences and some potential pitfalls compared to other deep learning models. We explain how a structure-prediction tool can impact many research fields, and in particular revolutionize the strategies for designing of effective next generation vaccines and chemical and biological drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
- RNA Research and Drug Discovery Center, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China.
- Integrative Science Center of Germplasm Creation in Western China (Chongqing) Science City, Biological Science Research Center, Southwest University, Chongqing 400715, China.
- Department of Graduate College, Zhejiang Chinese Medical University, Hangzhou 310000, China.
- The Joint Research Center, Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo 315000, China.
- Department of Medicine, Harvard Medical School, and Brigham and Women's Hospital, Boston, MA 02115, USA.
Förderung
- MOST
- Wenzhou Medical University
- National Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Fang, Z., Ran, H., Zhang, Y., Chen, C., Lin, P., Zhang, X., & Wu, M. (2025). AlphaFold 3: an unprecedent opportunity for fundamental research and drug development. Precision Clinical Medicine, 8(3). https://doi.org/10.1093/pcmedi/pbaf015
Vancouver
Fang Z, Ran H, Zhang Y, Chen C, Lin P, Zhang X, et al. AlphaFold 3: an unprecedent opportunity for fundamental research and drug development. Precision Clinical Medicine. 2025;8(3). doi:10.1093/pcmedi/pbaf015
BibTeX
@article{Fang2025,
author = {Fang, Ziqi and Ran, Hongbiao and Zhang, YongHan and Chen, Chensong and Lin, Ping and Zhang, Xiang and Wu, Min},
title = {AlphaFold 3: an unprecedent opportunity for fundamental research and drug development},
journal = {Precision Clinical Medicine},
year = {2025},
volume = {8},
number = {3},
doi = {10.1093/pcmedi/pbaf015}
}
EUVIMED